AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15717509 — intervention group
Group type: COMPARATOR
Intervention: Control group (no KT or propofol sedation)
Number of subjects: 46
Study 12101331 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Number of subjects: 122
Study 12101331 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 122
Study 10066989 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples with 1 drug-abusing partner (husband or wife)
Number of subjects: 287
Study 10066989 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples with both partners abusing drugs
Number of subjects: 287
Study 10066989 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples with 1 drug-abusing partner during and 1 year after treatment
Number of subjects: 287
Study 10066989 — intervention group
Group type: COMPARATOR
Intervention: Non-substance-abusing conflicted couples
Number of subjects: 287
Study 7644246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg, 8 mg)
Number of subjects: 10
Study 7644246 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl solution)
Number of subjects: 10
Study 2792787 — intervention group
Group type: EXPERIMENTAL
Intervention: Running exercise (REX) group engaged in a 12-week aerobic exercise conditioning program at 70% of their VO2max, 3 times a week for 30 minutes each session.
Number of subjects: 40
Study 2792787 — intervention group
Group type: COMPARATOR
Intervention: Isometric exercise (IEX) group engaged in a 12-week weight lifting program utilizing large muscle mass at 30% of their maximal voluntary contraction, 3 times a week for 30 minutes each session.
Number of subjects: 40
Study 973761 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruption of the patent ductus arteriosus (PDA) in 20 patients
Number of subjects: 42
Study 973761 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment in 13 patients
Number of subjects: 42
Study 29600837 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Training (FT)
Number of subjects: 44
Study 29600837 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Training (TT)
Number of subjects: 44
Study 29600837 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 44
Study 28619659 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 or 300 mg
Number of subjects: 666
Study 28619659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666
Study 26204970 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized care in an observation unit
Number of subjects: 0
Study 23909039 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative taxane-based chemotherapy
Number of subjects: 0
Study 22008302 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive self-ligating brackets (Damon 3 MX)
Number of subjects: 64
Study 22008302 — intervention group
Group type: EXPERIMENTAL
Intervention: Active self-ligating brackets (In-Ovation R)
Number of subjects: 64
Study 19593177 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 15
Study 19593177 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 15
Study 17000077 — intervention group
Group type: EXPERIMENTAL
Intervention: V.A.C. therapy
Number of subjects: 60
Study 17000077 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound care
Number of subjects: 60
Study 17000077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 15556824 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adenosine infusion (140 microg/kg/min for 22 minutes)
Number of subjects: 10
Study 15556824 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-endorphin bolus followed by infusion
Number of subjects: 10
Study 15556824 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone bolus followed by NaCl infusion
Number of subjects: 10
Study 15556824 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl bolus for 2 minutes followed by NaCl infusion for 15 minutes)
Number of subjects: 10
Study 11384898 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 117
Study 11384898 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 117
Study 11384898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 9402541 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic protocol for ocular palsies
Number of subjects: 105
Study 7667826 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg protamine/100 U UFH
Number of subjects: 15
Study 7667826 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg protamine/100 U UFH
Number of subjects: 15
Study 7667826 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg protamine/100 U UFH
Number of subjects: 15
Study 7667826 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg protamine/100 anti‐Xa U LMWH
Number of subjects: 15
Study 7667826 — intervention group
Group type: EXPERIMENTAL
Intervention: protamine on LMWH in shed blood
Number of subjects: 15
Study 7667826 — intervention group
Group type: COMPARATOR
Intervention: UFH and LMWH
Number of subjects: 15
Study 2531963 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous absorbable suture (Dexon)
Number of subjects: 238
Study 2531963 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nonabsorbable suture (Surgilon)
Number of subjects: 238
Study 2531963 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted absorbable suture (Dexon)
Number of subjects: 238
Study 2531963 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall frequency after 41 months follow-up
Number of subjects: 238
Study 31041523 — intervention group
Group type: EXPERIMENTAL
Intervention: CXL combined with antifungal medications (CXL‐M)
Number of subjects: 41
Study 31041523 — intervention group
Group type: COMPARATOR
Intervention: Antifungal medications alone (M)
Number of subjects: 41
Study 28495149 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 205
Study 28495149 — intervention group
Group type: COMPARATOR
Intervention: Sham control (riboflavin alone without removal of the epithelium)
Number of subjects: 205
Study 25645909 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion (75 g)
Number of subjects: 41
Study 25645909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose ingestion (75 g)
Number of subjects: 41
Study 25645909 — intervention group
Group type: COMPARATOR
Intervention: Baseline acyl-ghrelin
Number of subjects: 41
Study 25645909 — intervention group
Group type: COMPARATOR
Intervention: PYY response after glucose
Number of subjects: 41
Study 25645909 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY response after fructose
Number of subjects: 41
Study 22459694 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST intervention
Number of subjects: 0
Study 22459694 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21747296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 28
Study 21747296 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuously Moderate-Intensity Exercise (CME)
Number of subjects: 28
Study 21747296 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Interval Training (AIT) and Continuously Moderate-Intensity Exercise (CME)
Number of subjects: 28
Study 19262495 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine (4 mg day(-1) increased to 16 mg day(-1))
Number of subjects: 47
Study 19262495 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg day(-1) increased to 10 mg day(-1))
Number of subjects: 47
Study 18690917 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT and NA reuptake inhibitors (e.g., duloxetine)
Number of subjects: 0
Study 18690917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 18690917 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 18690917 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective 5‐HT reuptake inhibitors and SNRIs
Number of subjects: 0
Study 12813199 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic renogram with furosemide after vigorous intravenous hydration
Number of subjects: 205
Study 10639612 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 0
Study 10639612 — intervention group
Group type: COMPARATOR
Intervention: Sham exchange
Number of subjects: 0
Study 9264050 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam drops (test formulation)
Number of subjects: 24
Study 9264050 — intervention group
Group type: COMPARATOR
Intervention: Estazolam tablets (reference formulation, ESILGAN)
Number of subjects: 24
Study 8319321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuelin SA (sustained-release theophylline) 250 mg every 12 h plus Nuelin liquid (non-sustained-release theophylline) 100 mg, 200 mg, or 300 mg
Number of subjects: 12
Study 8319321 — intervention group
Group type: COMPARATOR
Intervention: Nuelin SA (sustained-release theophylline) 250 mg every 12 h plus placebo
Number of subjects: 12
Study 3621870 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg b.w. of TGLVP
Number of subjects: 8
Study 3621870 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline i.v.
Number of subjects: 8
Study 29063598 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified SLIPA with a 120° bend at the bridge point
Number of subjects: 134
Study 29063598 — intervention group
Group type: COMPARATOR
Intervention: Conventional SLIPA insertion method
Number of subjects: 134
Study 29063598 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study 28825973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (HIT)
Number of subjects: 318
Study 28825973 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 318
Study 25460263 — intervention group
Group type: EXPERIMENTAL
Intervention: BFNE-R (Brief Fear of Negative Evaluation Scale - Revised)
Number of subjects: 98
Study 25460263 — intervention group
Group type: EXPERIMENTAL
Intervention: FPES (Fear of Positive Evaluation Scale)
Number of subjects: 98
Study 25460263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pride responses to positive films
Number of subjects: 98
Study 23308216 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive rapid HIV tests
Number of subjects: 62
Study 23308216 — intervention group
Group type: COMPARATOR
Intervention: Participants who completed confirmatory testing
Number of subjects: 62
Study 23308216 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected true HIV cases lost at confirmation stage
Number of subjects: 62
Study 21386766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 32 mg/day
Number of subjects: 514
Study 21386766 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 514
Study 18202320 — intervention group
Group type: EXPERIMENTAL
Intervention: Far infrared (FIR) therapy
Number of subjects: 0
Study 18202320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin (mimicking FIR therapy)
Number of subjects: 0
Study 18202320 — intervention group
Group type: COMPARATOR
Intervention: HO inhibitor (tin protoporphyrin-IX)
Number of subjects: 0
Study 18202320 — intervention group
Group type: COMPARATOR
Intervention: Selective knockdown of HO-1
Number of subjects: 0
Study 18202320 — intervention group
Group type: EXPERIMENTAL
Intervention: FIR therapy in patients undergoing hemodialysis
Number of subjects: 0
Study 16391189 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG SPECT
Number of subjects: 130
Study 12857503 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Group A)
Number of subjects: 60
Study 12857503 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg esmolol (Group B)
Number of subjects: 60
Study 12857503 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg/kg fentanyl (Group C)
Number of subjects: 60
Study 12857503 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg esmolol combined with 2 microg/kg fentanyl (Group D)
Number of subjects: 60
Study 11020410 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylic intraocular lens
Number of subjects: 1202
Study 11020410 — intervention group
Group type: COMPARATOR
Intervention: Polymethylmethacrylate intraocular lens
Number of subjects: 1202
Study 8864674 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 61
Study 8864674 — intervention group
Group type: COMPARATOR
Intervention: 15 mg prednisolone
Number of subjects: 61
Study 1624977 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling/supportive interventions by a community health nurse (CHN)
Number of subjects: 30
Study 1624977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (followed through pregnancy and first 6 months of babies' lives)
Number of subjects: 30
Study 1624977 — intervention group
Group type: COMPARATOR
Intervention: Control group (evaluated when infant reached 6 months)
Number of subjects: 30
Study 6367947 — intervention group
Group type: EXPERIMENTAL
Intervention: S1: CYVADIC (combination chemotherapy with cyclophosphamide, vincristine, Adriamycin, and DTIC administered simultaneously every 4 weeks)
Number of subjects: 246
Study 6367947 — intervention group
Group type: COMPARATOR
Intervention: S2: ADIC-CYV (pairs of drugs administered alternating at 4 weekly intervals)
Number of subjects: 246
Study 6367947 — intervention group
Group type: EXPERIMENTAL
Intervention: S1: CYVADIC
Number of subjects: 246
Study 6367947 — intervention group
Group type: COMPARATOR
Intervention: S2: ADIC-CYV
Number of subjects: 246
Study 6367947 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky index (KI) 90-100
Number of subjects: 246
Study 6367947 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky index (KI) 50-80
Number of subjects: 246
Study 6367947 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky index (KI) 50
Number of subjects: 246
Study 31673366 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 45
Study 31673366 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Number of subjects: 45
Study 31673366 — intervention group
Group type: EXPERIMENTAL
Intervention: Early BOS
Number of subjects: 45
Study 28591082 — intervention group
Group type: EXPERIMENTAL
Intervention: SoluMatrix indomethacin 40 mg 3 times daily
Number of subjects: 462
Study 28591082 — intervention group
Group type: EXPERIMENTAL
Intervention: SoluMatrix indomethacin 20 mg 3 times daily
Number of subjects: 462
Study 28591082 — intervention group
Group type: EXPERIMENTAL
Intervention: SoluMatrix indomethacin 40 mg twice daily
Number of subjects: 462
Study 28591082 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg loading dose followed by 200 mg twice daily
Number of subjects: 462
Study 28591082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 25526970 — intervention group
Group type: COMPARATOR
Intervention: Suvorexant 40/30 mg
Number of subjects: 2040
Study 25526970 — intervention group
Group type: COMPARATOR
Intervention: Suvorexant 20/15 mg
Number of subjects: 2040
Study 25526970 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 2040
Study 24965313 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) exercises accompanied by music
Number of subjects: 66
Study 24965313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study 22970149 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day DHA (from algal oil)
Number of subjects: 362
Study 22970149 — intervention group
Group type: COMPARATOR
Intervention: Taste/color matched corn/soybean oil placebo
Number of subjects: 362
Study 20580201 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare management
Number of subjects: 405
Study 20580201 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 405
Study 18042824 — intervention group
Group type: EXPERIMENTAL
Intervention: HATS analysis software
Number of subjects: 150
Study 18042824 — intervention group
Group type: COMPARATOR
Intervention: Odontorule slide rule (manual measurement)
Number of subjects: 150
Study 18042824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 150
Study 15627725 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human leptin (4 microg ml(‐1) kg(‐1) body weight)
Number of subjects: 12
Study 15627725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 11840415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus carboplatin for four cycles followed by four cycles of paclitaxel plus carboplatin
Number of subjects: 0
Study 11840415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin or carboplatin
Number of subjects: 0
Study 11840415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus paclitaxel
Number of subjects: 0
Study 11840415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus topotecan
Number of subjects: 0
Study 11840415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus liposome‐encapsulated doxorubicin
Number of subjects: 0
Study 11840415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine
Number of subjects: 0
Study 11840415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus treosulfan
Number of subjects: 0
Study 11840415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus a platinum compound
Number of subjects: 0
Study 10544992 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-focused case management
Number of subjects: 119
Study 10544992 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-focused case management plus consumer advocacy
Number of subjects: 119
Study 10544992 — intervention group
Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 119
Study 7560254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg every 12 hours (n = 12)
Number of subjects: 18
Study 7560254 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 hours (n = 6)
Number of subjects: 18
Study 7560254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg every 12 hours
Number of subjects: 18
Study 7560254 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin daily for 14 days
Number of subjects: 18
Study 2182370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd YAG laser
Number of subjects: 143
Study 2182370 — intervention group
Group type: EXPERIMENTAL
Intervention: Heater probe
Number of subjects: 143
Study 2182370 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic therapy (Control)
Number of subjects: 143
Study 7370482 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (up to 225 mgs nocte for 8 months)
Number of subjects: 40
Study 7370482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nightly for 8 months)
Number of subjects: 40
Study 31154289 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg, s.c., weekly) + Methotrexate (7.5-15 mg, p.o., weekly)
Number of subjects: 30
Study 31154289 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg, s.c., weekly)
Number of subjects: 30
Study 31154289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (Etanercept + Methotrexate)
Number of subjects: 30
Study 31154289 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy group (Etanercept)
Number of subjects: 30
Study 28060936 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal Jelly (RJ) 1200 mg/tablet, six tablets daily for 8 weeks
Number of subjects: 43
Study 28060936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 25636315 — intervention group
Group type: EXPERIMENTAL
Intervention: Caribbean Informed Parents and Children Together
Number of subjects: 1833
Study 23716707 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion
Number of subjects: 114
Study 23716707 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion (defined as time to maximum volume of 59% or greater)
Number of subjects: 114
Study 21122974 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated external defibrillator (AED) presence and instructions visible
Number of subjects: 90
Study 21122974 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated external defibrillator (AED) presence
Number of subjects: 90
Study 21122974 — intervention group
Group type: COMPARATOR
Intervention: CPR certificate status
Number of subjects: 90
Study 21122974 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance in simulated cardiac arrest
Number of subjects: 90
Study 19593546 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cardiac output monitoring devices
Number of subjects: 0
Study 17173898 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion mapping with color Doppler ultrasound and laser Doppler flowmeter for TESE biopsies.
Number of subjects: 12
Study 17173898 — intervention group
Group type: EXPERIMENTAL
Intervention: Areas with different levels of perfusion marked with needles and biopsies taken for TESE and histology.
Number of subjects: 12
Study 15510039 — intervention group
Group type: EXPERIMENTAL
Intervention: HSA-coated tympanostomy tubes
Number of subjects: 179
Study 15510039 — intervention group
Group type: EXPERIMENTAL
Intervention: HSA-coated tympanostomy tubes in patients with perioperative bleeding
Number of subjects: 179
Study 15510039 — intervention group
Group type: COMPARATOR
Intervention: Uncoated tympanostomy tubes (control)
Number of subjects: 179
Study 11466802 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement not to smoke
Number of subjects: 0
Study 9631964 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty followed electively with Gianturco Roubin II stents (group I)
Number of subjects: 104
Study 9631964 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty alone (group II)
Number of subjects: 104
Study 7948056 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine at a mean dose of 166 +/- 48 mg
Number of subjects: 19
Study 7948056 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of trimipramine
Number of subjects: 19
Study 3282026 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder
Number of subjects: 787
Study 3282026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminder
Number of subjects: 787